Daré Bioscience, Inc. (DARE) Stock

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to enhancing women's health through the development and commercialization of innovative therapies. Focused on areas such as contraception, fertility, and sexual and vaginal health, Dare Bioscience identifies and advances novel product candidates to address unmet needs in these critical areas of women's healthcare.

The company's current flagship product, XACIATO, is a single-dose vaginal gel prescribed for the treatment of bacterial vaginosis in females aged 12 years and older. Dare Bioscience also boasts an impressive pipeline of advanced clinical products. Notable candidates include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a topical cream formulation of sildenafil designed to treat female sexual arousal disorder when applied to the vulva and vagina.

In addition to its advanced clinical portfolio, Dare Bioscience is progressing several Phase 1-ready products. These include DARE-HRT1, an intravaginal ring combining bio-identical estradiol and progesterone for the treatment of vasomotor symptoms associated with hormone therapy; and DARE-VVA1, a vaginally delivered tamoxifen formulation aimed at addressing vulvar and vaginal atrophy in hormone-receptor positive breast cancer patients. With a robust pre-clinical pipeline as well, Dare Bioscience continues to innovate with products like DARE-LARC1, a combination contraceptive product offering reversible contraception, and DARE-RH1, a non-hormonal contraceptive for both men and women.